Skip to main content

Table 2 Participant characteristics

From: Patient experiences, attitudes and expectations towards receiving information about anti-TNF medication – “It could give me two heads and I’d still try it!”

Pseudonym Age (years) Time since RA diagnosis (years) Current anti-TNF agent Time since commenced anti-TNF (years) Pre-therapy DAS28 score
Male group:
Robert 85 21 Etanercept 4 8.47
Steve 47 17 Etanercept 9 5.75
Jim 57 18 Etanercept 1 6.20
Bob 79 21 Adalimumab 7 5.57
Terry 46 11 Adalimumab 2 6.90
Female group:      
Katherine 64 5 Adalimumab 2 7.08
Helen 62 10 Adalimumab 8 6.07
Val 64 26 Adalimumab 7 7.94
Claire 63 15 Etanercept 6 5.92
Sally 67 21 Etanercept 4 6.53